🔎 Trials Near Me

Home › Rhabdoid Tumor

Rhabdoid Tumor clinical trials recruiting in the U.S.

17 studies for Rhabdoid Tumor are recruiting participants at sites across the United States.

Cities with the most studies

By state

Recently updated studies

GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults

RecruitingPhase 1
Ages 1 to 30 · All sexes · Updated Sep 11, 2026 · NCT07087002

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

RecruitingPhase 1
36 Months – 22 Years · All sexes · Updated Sep 4, 2026 · NCT03911388

B7-H3.CD28Z.CART in CNS Neoplasms

RecruitingPhase 1
Ages 2 to 21 · All sexes · Updated Sep 3, 2026 · NCT07390539

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

RecruitingPhase 1/2
Up to age 26 · All sexes · Updated Sep 3, 2026 · NCT06465199

C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)

RecruitingPhase 1
12 Months – 25 Years · All sexes · Updated Aug 3, 2026 · NCT04099797

Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors

RecruitingPhase 1/2
6 Months – 25 Years · All sexes · Updated Jun 30, 2026 · NCT06625190

Study of Novel Therapies for Young People With Recurrent/Progressive Atypical Teratoid Rhabdoid Tumor (ATRT)

RecruitingPhase 2
Ages 1 to 39 · All sexes · Updated Jun 23, 2026 · NCT07447076

Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)

RecruitingPhase 1
Ages 1 to 30 · All sexes · Updated Jun 17, 2026 · NCT06193759

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

RecruitingPhase 1
Up to age 21 · All sexes · Updated May 19, 2026 · NCT04897321

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated May 19, 2026 · NCT04901702

A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors

RecruitingPhase 2
12 Months · All sexes · Updated May 6, 2026 · NCT05985161

Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells

RecruitingPhase 1
Up to age 21 · All sexes · Updated Nov 3, 2025 · NCT06198296

A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

RecruitingPhase 2
18 Months – 40 Years · All sexes · Updated Aug 12, 2025 · NCT05135975

From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.